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fortunately, each technique is associated with significant
risks and complications inherent to their clinical use, and
none has been so successful as to become a standard of care.
The assumption is usually made that most of the damage
resulting from ischemia/reperfusion of the spinal cord
occurs during the ischemic period. Therefore, the use of
hypothermia and other technical approaches for preventing
spinal cord injury has focused on protective measures dur-
ing the ischemic period or “cross-clamp time,” rather than
on injury that might occur during reperfusion.
One pharmacologic approach to decreasing spinal
cord reperfusion inflammation includes the use of steroids
before and immediately after aortic clamp release. One
report by Laschinger et al7 described reduced paraplegia
rates in animals receiving perioperative methylpred-
nisolone. In 1998 Kanellopoulos et al8 reported reduction
in neuronal apoptosis in a rat when given a preoperative
dose of methylprednisolone. These observations support
development of an anti-inflammatory drug to reduce
spinal cord reperfusion injury and neuronal apoptosis
without the prohibitive side effects associated with sys-
temic steroids.
Partial protection of the spinal cord from ischemic insult
during thoracic aortic surgery can be achieved by many
methods. The most frequently used techniques include the
cooling of the ischemic segment of cord, the use of partial
or total cardiopulmonary bypass grafting, injection of cold
solutions into the isolated segment of aorta, and perfusion
of the paraspinal spaces with cold solutions.1-6 Un-
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Background: We hypothesized that systemic ATL-146e, an adenosine A2A agonist, would decrease spinal cord reperfu-
sion inflammatory stress and inhibit apoptosis and that these effects would correlate with improved neurologic func-
tional outcome.
Methods: Thirty rabbits underwent cross-clamping of the infrarenal aorta for 45 minutes. One group of animals (n =
14) received 0.06 µg/kg per minute of ATL-146e infused intravenously for 3 hours, beginning 15 minutes before
reperfusion. A second group of animals (n = 16) underwent spinal cord ischemia with saline vehicle alone and served
as ischemic controls. Animals (n = 9, 11) from each group survived for 48 hours and assessed for neurologic impair-
ment with the Tarlov (0-5) scoring system. Four animals from each group were humanely killed at the end of the 
3-hour treatment period, and the remainder killed after 48 hours’ survival. In all animals, lumbar spinal cord tissue
specimens were frozen for subsequent Western blot analysis of heat shock protein 70 (HSP 70), and for the p85 frag-
ment of poly (ADP-ribose) polymerase (PARP). Neuronal viability indices were determined at 48 hours with hema-
toxylin and eosin staining.
Results: There was improvement in neurologic function in rabbits receiving ATL-146e (P < .001) compared with
ischemic controls. At the end of the 3-hour treatment period there was a 46% (P < .05) decrease in HSP 70 expression
in the ATL-146e group compared with the control group, but no difference in PARP expression. At 48 hours, there
was no difference between control and ATL-146e groups in HSP 70 expression, but there was a 65% (P < .05) reduc-
tion in PARP in the spinal cords of animals that had received ATL-146e. There was a significant improvement in neu-
ronal viability indices in animals receiving ATL-146e compared with ischemic controls (P < .05).
Conclusions: Systemic ATL-146e infusion during reperfusion after spinal cord ischemia results in preservation of
hindlimb motor function. There is evidence of decreased spinal cord inflammatory stress immediately after treatment
with ATL-146e as indicated by reduced HSP 70 induction. Treatment with ATL-146e is associated with a reduction
in neuronal apoptosis as suggested by a substantial decrease in the fragmentation of PARP at 48 hours. These results
suggest that inflammation during reperfusion and subsequent apoptosis contribute to paralysis after restoration of
blood flow to the ischemic spinal cord. (J Vasc Surg 2001;34:482-8.)
We have previously reported that the ischemic spinal
cord can be protected by retrograde venous spinal cord
perfusion with a cold adenosine-enhanced crystalloid
solution.9 In the porcine model, adenosine appears to
produce some degree of added protection compared
with cooling alone. We hypothesized that adenosine
might protect the ischemic spinal cord either by activa-
tion of inhibitory A1 receptors on neuronal cells10 or by
activation of A1 or A3 adenosine receptors that precon-
dition the spinal cord.11 More recent work with adeno-
sine analogs has indicated that the anti-inflammatory
effects of A2A receptor activation may diminish reperfu-
sion injury by blocking activated leukocyte-endothelial
interaction.
Heat shock protein 70 (HSP 70) is a neuronal chap-
erone molecule that is upregulated during periods of phys-
iologic stress such as ischemia and inflammation.
Augmentation of neuronal HSP 70 protein levels has been
observed up to 4 days after ischemic spinal cord injury in
the rabbit.12,13 HSP 70 induction is known to also corre-
late with DNA fragmentation and apoptosis in the rat
brain after ischemic insult.14 The release of inflammatory
cytokines such as tumor necrosis factor α (TNF-α) from
inflamed tissues activates a signaling cascade that ulti-
mately causes the upregulation of caspases and eventual
fragmentation of the DNA repair protein poly (ADP-
ribose) polymerase (PARP).15 The tissue levels of PARP
cleavage products, including the p85 subunit, are closely
correlated with neuronal apoptosis.16 This is described in
a study by Shackelford et al,17 who revealed that cleavage
of PARP and decreased total intact PARP levels that cor-
related directly with the duration of spinal cord
ischemia/reperfusion in a rabbit model. In our study we
have used spinal cord levels of HSP 70 and p85 PARP as
indices of postischemic inflammatory stress and apoptosis,
respectively.
ATL-146e is a potent and selective agonist of A2A
adenosine receptors. This compound has been shown to
attenuate ischemia/reperfusion injury by activating
endothelial A2A receptors in the rat kidney.18 We hypoth-
esized that infusion of ATL-146e during reperfusion after
spinal cord ischemia would reduce the expression of HSP
70, a marker of inflammatory stress, and improve neuronal
viability through inhibition of apoptosis as demonstrated
by decreased fragmentation of PARP, and that these
effects would correlate with improved neurologic func-
tional outcome.
METHODS
All protocols were reviewed and approved by the
Animal Review Committee of the University of Virginia.
All animals received humane care in compliance with the
Guide for the Care and Use of Laboratory Animals as
described by the Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research Council
(Washington: National Academy Press, 1996).
Animal surgery. Thirty New Zealand rabbits
(weight, 3.0-3.5 kg) were selected and acclimatized for a
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minimum of 3 days within our vivarium. Each was anes-
thetized with an intramuscular injection of xylazine (10
mg) and ketamine (100 mg). An ear vein catheter was
placed for the administration of additional medications
and intravenous fluids. The animals were intubated, placed
supine on a heated operating table, and ventilated with a
mixture of 98% oxygen and 2% halothane. Core body tem-
perature was maintained at 36.5 ± 0.5°C. An ear arterial
catheter was placed for continuous monitoring of arterial
pressure. Heparin sodium (2000 units) was administered
intravenously and allowed to circulate for 5 minutes.
During this interval, the abdomen was prepared and
draped in a sterile fashion. A midline laparotomy was
made, and the viscera reflected to the right. After the
retroperitoneum was opened, the abdominal aorta and
inferior vena cava were collectively clamped with Satinsky
clamps just distal to the left renal artery and again proxi-
mal to the aortoiliac bifurcation (Fig 1). This technique
exploits the segmental arterial anatomy of the rabbit lum-
bar spinal cord. The placement of two clamps theoretically
decreases the likelihood there will be intervening lumbar
collaterals that could undermine efforts to ensure spinal
cord ischemia. Additionally, this technique has reliably
resulted in lumbar spinal cord ischemia in our past experi-
Fig 1. Illustration of operative technique for subjecting the rab-
bit lumbar spinal cord to ischemia. Note proximal clamp is placed
just distal to left renal artery, excluding any intervening lumbar
collaterals. CELIAC A, Celiac artery; IMA, inferior mesenteric
artery; SMA, superior mesenteric artery.
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ence.5 Each animal underwent 45 minutes of warm spinal
cord ischemia, with the clamps removed just before clo-
sure. Pulse oximetry ensured adequate oxygenation
throughout the procedure.
Drug administration. ATL-146e (4-{3-[6-Amino-
9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-
yl)-9H-purin-2-yl]-prop-2-ynyl}-cyclohexanecarboxylic
acid methyl ester) was synthesized and chemically charac-
terized within the chemistry department at our institu-
tion.19 This compound is a selective agonist of A2A
adenosine receptors that is based on competition for radi-
oligand binding to recombinant human adenosine recep-
tor subtypes and inhibits the oxidative burst of
neutrophils.20 One group of animals (n = 14) received
0.06 µ/kg per minute of intravenous ATL-146e for 3
hours, which began 15 minutes before clamp removal
(after 30 minutes if there was ischemia). A second cohort
(n = 16) received saline vehicle and served as an ischemic
control group.
Physiologic testing. Animals were recovered postop-
eratively and given food and water ad lib. At 24 and 48
hours after surgery, hindlimb neurologic function was
evaluated in eight animals with the following modified
Tarlov scoring system: 0 = atony, 1 = slight movement, 2
= sits with assistance, 3 = sits alone, 4 = weak hop, 5 =
normal gait/hopping. The same technician performed all
neurologic functional evaluations in a blinded fashion.
Western blot analysis. During necropsy all animals
underwent rapid lumbar laminectomy and extraction of
the spinal cord correlating to the zone of ischemic
injury. Tissue was frozen in liquid nitrogen and stored at
–80°C until protein analysis was performed. Cellular
protein (80 µg per well) was fractionated on a 7.5%
(weight per volume) sodium dodecyl sulfate polyacry-
lamide gel and transferred to nitrocellulose with an elec-
trophoretic transfer cell (BioRad, Hercules, Calif). The
blot was blocked in 5% milk and 1×TBST (50 mmol/L
Tris HCl, pH 7.4, 150 mmol/L NaCl, 0.1% polysorbate
[Tween]) and incubated either with (1:1500 dilution)
monoclonal mouse-antihuman antibody against HSP 70
(StressGen Biotechnologies Corp, Victoria, BC) or with
(1:100 dilution) polyclonal goat-antimouse p85 fragment
of PARP (Santa Cruz Biotechnology, Santa Cruz, Calif)
for 2 hours at room temperature, followed by washing
with l×TBST. The blot was then incubated for 1 hour
with secondary antibody coupled to horseradish peroxi-
dase and washed. Protein was visualized with chemilumi-
nescence (ECL; Amersham, Amersham Pharmacia,
Piscatoway, NJ) and quantitated with densitometry.
Neuronal viability index. During necropsy, lumbar
sections of spinal cord (n = 8 per group) from the ischemic
zone of injury (23-27 cm from foramen magnum) were
fixed in 10% formalin and paraffin embedded for section-
ing. Four-µm-thick sections were affixed to glass slides (2-
4 per slide), deparaffinized in xylene, and rehydrated in
serial dilutions of ethanol. Slides were stained with Harris’
hematoxylin and counterstained with eosin-phloxine solu-
tion for 2 minutes.
All sections were reviewed in a blinded fashion by the
same observer and evaluated quantitatively. Features con-
sistent with neuronal injury included eosinophilic cyto-
plasm, vacuolization, and pyknotic appearance (loss of
nuclear structure). Cells that contained Nissl substance in
the cytoplasm, loose chromatin, and prominent nucleoli
were considered viable. The neurons from each spinal cord
section were examined by a blinded observer and catego-
rized into two subtypes: those appearing clearly viable and
those appearing clearly injured. Neurons without clear
morphologic features of either category were excluded
from numerical assessment. The viability index was calcu-
lated as the number of clearly viable neurons divided by
the total neuronal count within the entire microscopic sec-
tion for each animal. Generally, this method resulted in
the exclusion of five to 10 neurons per specimen, which
had a mild impact on the denominator (range, 56-143
neurons per specimen).
Statistical analysis. The number of subjects (at least
8 per group) was determined so that a there was an 85%
chance of detecting a difference in a Tarlov score of 2 or
more at the 0.05 level of statistical significance. All results
are expressed as the mean ± SEM. Tarlov score results are
compared by means of the Mann-Whitney U test.
Hemodynamic data, histologic data, and relative densito-
metries were analyzed for between-group differences with
the Student t test. Significance was defined as a P value less
than .05, as determined with SPSS Software (SPSS Inc,
Chicago, Ill).
RESULTS
Operative outcome. Thirteen experimental rabbits
and 15 ischemic controls survived the procedure. One
rabbit from the experimental group and one animal from
the control group died within the first 24 hours and were
excluded from statistical analysis. Experimental animals
experienced minor transient changes in mean arterial
pressure and heart rate on initiation of the ATL-146e,
but there was no significant difference in hemodynamic
parameters between experimental and control groups
(Fig 2). Both groups demonstrated a reduction in mean
arterial pressure after aortic cross-clamp removal.
Adequate urine output was maintained throughout the
operative procedure.
Neurologic outcome. There was a significant
improvement in hindlimb motor function in rabbits
receiving ATL-146e (Tarlov = 4.4 ± 0.26; P < .001) com-
pared with ischemic control animals (Tarlov = 0.5 ± 0.4;
Fig 3).
Measurement of HSP 70. There was a 46% (P <
.05) decrease in HSP 70 expression in animals receiving
ATL-146e, measured immediately at the end of the 3-
hour treatment period. However, there was no significant
difference in HSP 70 expression at 48 hours (Fig 4).
Measurement of p85 PARP. There was no signifi-
cant difference in p85 PARP fragment expression between
the vehicle and ATL-146e treatment groups in spinal 
cord samples taken immediately at the end of the 3-hour
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reperfusion-treatment period. There was a 65% decrease
(P < .05) in the p85 PARP fragment expression after 48
hours in rabbits that had received ATL-146e during the
first 3 hours of reperfusion (Fig 5). Although it was also
possible to measure protein levels at 116 kd, there was no
detectable band in this experiment.
Neuronal viability index. There was a significant
improvement in the viability index (n = 8, 8) for animals
receiving ATL-146e during reperfusion (0.61 ± 0.15, P <
.05) versus controls (0.26 ± 0.13; Fig 6). Although the
entire surface area for each section was reviewed, most of
the neuronal cell bodies were observed in the ventral horn
motor column. Therefore, these measurements generally
reflect motor neuronal viability. There was no evidence of
a “no reflow” phenomenon on histologic examination of
the microcapillary system of the spinal cord, suggesting
that some collateral flow may still remain, even with prox-
imal and distal aortic clamping.
DISCUSSION
Previously, we have shown that retrograde venous
infusion of cold adenosine in saline into the hemiazygous
Fig 2. Comparison of mean arterial pressure trends in control and ATL-146e (A2A) groups as function of
operative time and reperfusion interval. Cross-clamp removal is indicated at T = 0 time point (P = not sig-
nificant at all time points).
Fig 3. Comparison of neurologic functional outcome 48 hours after spinal cord ischemia/reperfusion in
animals given systemic ATL-146e versus control. Data are expressed as means ± SEM. Statistical analysis
by Mann-Whitney rank sum. Asterisk indicates P < .001; N = 11, 9).
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system during aortic cross-clamping improves neurologic
outcome in a swine model of spinal cord ischemia.21 At
that time it seemed likely that the inhibitory effects of A1
receptors on neuronal cells might contribute to the
spinal cord protection afforded by cold adenosine. We
also considered vasodilatation during cross-clamping, as
mediated by A2A or A2B receptors, as a possible protec-
tive mechanism to reduce absolute ischemia. On the basis
of these assumptions, adenosine was not given during the
reperfusion period in these early experiments. The cur-
rent study indicates that a selective A2A agonist, ATL-
146e, reduces spinal cord injury by a mechanism that
does not involve A1 receptors or vasodilatation during
ischemia. We started a 3-hour intravenous infusion of the
compound 15 minutes before reperfusion to allow blood
levels of the compound to accumulate to a steady state
before the initiation of reperfusion. The data suggest
that most or all of the substantial protective effects of
ATL-146e occur during the first 3 hours of reperfusion
after spinal cord ischemia.
Adenosine protects tissues from traumatic or ischemic
injury through multiple receptor subtypes. The activation
Fig 5. Representative Western blots and densitometry of p85 PARP expression in spinal cord tissue taken
from ischemic zone of spinal cord injury at end of compound infusion period (acute) or after 48 hours of
reperfusion. Lysates from animals receiving ATL-146e (A2A) demonstrated decreased PARP p85 levels at
48 hours. Section mark indicates P = .02l N = 4 all groups. All other comparisons revealed no significant
differences.
Fig 4. Representative Western blots and densitometry comparing HSP 70 expression in tissues taken from
ischemic zone of spinal cord injury in animals receiving ATL-146e (A2A) and control animals at end of
compound infusion period (acute) and after 48 hours of reperfusion (N = 4 all groups). Acute A2A expres-
sion of HSP 70 was significantly decreased compared with acute control. Number sign indicates P = .002;
48-hour control, P = .04; 48-hour A2A, P = .005. There was no difference in HSP 70 expression between
48-hour control and 48-hour A2A groups.
of A1 and possibly A3 receptors produces preconditioning
to protect the heart and other tissues from subsequent
ischemic injury.22 In contrast to preconditioning, agonists
of A2A receptors can protect tissues from ischemia/reper-
fusion injury when given during the reperfusion period.
The A2A-selective agonist, CGS21680, has been found to
attenuate reperfusion injury in the dog heart.23 This effect
was correlated with an inhibition of coronary endothelial
adherence, neutrophil accumulation, and superoxide gen-
eration, suggesting that reduced inflammation may be
responsible for protecting the heart during reperfusion.
Using the rabbit model, we have demonstrated in our
laboratory that systemic ATL-146e administration
decreases neutrophil extravasation in the zone of spinal
cord ischemic/reperfusion.24 We think this finding is
related to the ubiquitous existence of endogenous A2A
receptors throughout the capillary endothelium and to
leukocytes. Numerous investigators have examined the
role of HSPs in conferring a preconditioning advantage
against subsequent ischemic neuronal injury.12,25 A recent
study describes preconditioning rabbits with 6 minutes of
spinal cord ischemia, followed by 26 minutes of aortic
occlusion.26 Preconditioning caused an increase in spinal
cord HSP 72 levels, but no neuroprotective advantage.
Instead, it appears that HSP upregulation is a sensitive
indication of ischemic stress, but unto itself does not reli-
ably protect neurons from subsequent injury. In the cur-
rent study, we used the closely related HSP 70 as an index
of neuronal stress, and even though induction was
observed after ischemia/reperfusion, this survival mecha-
nism did not correlate with an improvement in functional
outcome. Forty-five minutes of spinal cord ischemia may
be too great a physiologic insult for HSPs to provide a sig-
nificant protective effect.
The induction of neuronal apoptotic events by an
ischemia/reperfusion injury-stimulus likely contributes to
the clinical observation of progressive loss of lower
extremity neurologic function over time after thoracic aor-
tic reconstruction.27 In a rabbit model, Sakurai et al28
identified selective and delayed spinal cord neuronal loss
after ischemia as a function of apoptosis, rather than sim-
ple necrosis. These clinical and experimental observations
are consistent with our current findings that adenosine
A2A therapy administered during reperfusion decreases
paralysis, and this is correlated with improved neuronal
viability and decreased evidence of neuronal apoptosis.
In our experiment simple histologic analysis does not
discern necrosis from apoptosis. Rather, it is inferred that
ATL-146e treatment maintains neuronal viability, particu-
larly in the ventral motor column. The findings of
increased HSP 70 levels and subsequent fragmentation of
PARP in control spinal cord cellular lysates support the
idea that the active process of apoptosis is taking place
subsequent to ischemia and reperfusion injury. This effect
is significantly limited in rabbits receiving ATL-146e dur-
ing reperfusion. We chose to measure the fragmentation
of PARP after failed attempts to perform TUNEL assay on
rabbit spinal cord specimens. The primary impasse with
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many of the tests for apoptosis is related to nonreactivity
in the rabbit species. Although PARP is not absolutely
required for apoptosis to proceed, the cleavage of PARP
may contribute to the irreversibility of apoptosis. The
cleavage of this DNA repair protein is an end process
related to caspase-mediated cell death.15 We have
attempted to measure both caspase activity and protein
levels, but we were unsuccessful with Western blot tech-
niques.
ATL-146e decreases the release of TNF-α from
human monocytes and macrophages.29 Decreased local
and systemic TNF-α release as a result of ATL-146e infu-
sion at the time of reperfusion protects the spinal cord by
suppressing TNF-α–induced neuronal death signaling cas-
cades.15 TNF-α receptors propagate signaling events
through the downstream transcription factors such as
nuclear factor kappa B, upregulation of caspases, and even-
tual fragmentation of the DNA repair protein PARP with
attrition of viable spinal cord neurons.29,35 In this fashion,
we propose that ongoing cellular injury is initiated by an
inflammatory event. It is probable that multiple inflam-
matory cytokines other than TNF-α also contribute to this
apoptotic cascade.
Our experiment supports several conclusions about
ischemia/reperfusion neurologic injury. First, because the
protective agent, ATL-146e is observed to improve neu-
rologic outcome if given during the initial 3 hours of
reperfusion, it appears that a major contributor to neuro-
logic injury occurs during early reperfusion rather than the
ischemic interval itself. Protective events occurring during
this early reperfusion period not only appear to have an
impact on the immediate neurologic outcome demon-
strated by reduced HSP 70 induction but also may have
delayed benefits in protecting neurons from apoptosis and
loss of function at 48 hours. Second, systemic administra-
tion of ATL-146e is effective, rather than regional spinal
cord perfusion, implying that treatment of blood con-
stituents protects the spinal cord from the localized
inflammatory insult of spinal cord ischemia/reperfusion.
Finally, ATL-146e has multiple cellular and humoral
immunomodulatory effects, not only decreasing neu-
Fig 6. Graphic comparison of neuronal viability indices calcu-
lated from hematoxylin and eosin staining of formalin-fixed spinal
cord sections from zone of ischemic injury (N = 8, 8; @, P < .05).
trophil and platelet adherence at the time of injury, but
possibly decreasing initiation of TNF-α–induced neuronal
apoptosis. The neuroprotective activity of purinergic
drugs such as ATL-146e may allow new insight into ther-
apeutic intervention for debilitating spinal cord injury
where reperfusion inflammation is the prevalent mecha-
nism.
We wish to express our grateful appreciation to Mr
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